Cite
62 - Safety Following Autologous Transplantation with Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in the Northstar Hgb-204 Study.
MLA
Walters, Mark C., et al. “62 - Safety Following Autologous Transplantation with Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in the Northstar Hgb-204 Study.” Biology of Blood & Marrow Transplantation, vol. 24, Mar. 2018, p. S74. EBSCOhost, https://doi.org/10.1016/j.bbmt.2017.12.643.
APA
Walters, M. C., Kwiatkowski, J. L., Rasko, J. E. J., Hongeng, S., Schiller, G. J., Anurathapan, U., Cavazzana, M., Ho, P. J., von Kalle, C., Kletzel, M., Leboulch, P., Vichinsky, E. P., Deary, B., Asmal, M., & Thompson, A. A. (2018). 62 - Safety Following Autologous Transplantation with Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in the Northstar Hgb-204 Study. Biology of Blood & Marrow Transplantation, 24, S74. https://doi.org/10.1016/j.bbmt.2017.12.643
Chicago
Walters, Mark C., Janet L. Kwiatkowski, John E.J. Rasko, Suradej Hongeng, Gary J. Schiller, Usanarat Anurathapan, Marina Cavazzana, et al. 2018. “62 - Safety Following Autologous Transplantation with Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in the Northstar Hgb-204 Study.” Biology of Blood & Marrow Transplantation 24 (March): S74. doi:10.1016/j.bbmt.2017.12.643.